Cero Therapeutics Holdings, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OQB
CERo Therapeutics Holdings, Inc. filed an amendment to its 2025 Annual Report to provide required Part III disclosures regarding directors, executive compensation, and governance.
OQB
CERo Therapeutics Holdings, Inc. outlines the material terms of its common and preferred stock, including various series of convertible preferred stock and outstanding warrants.
OQB
CERo Therapeutics Holdings files an amendment to its annual report to include information required by Part III of Form 10-K, covering details about directors, executive officers, compensation, and corporate governance.
OQB
CERo Therapeutics' 2024 10-K filing reveals ongoing losses, clinical trial advancements, and substantial doubt about its ability to continue as a going concern.
OQB
CERo Therapeutics Holdings, Inc. outlines the terms of its common and preferred stock, as well as various warrants, in a recent 10-K filing.